References
- Kashiwagi T, Okada Y, Nomoto K. Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan. Paediatr Drugs. 2018;20(1):97-104. doi: 10.1007/s40272-017-0264-y. Erratum in: Kashiwagi T, Okada Y, Nomoto K. Correction to: Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan. Paediatr Drugs. 2018;20(3):291. doi: 10.1007/s40272-018-0291-3
- Roglić S. Infekcije djece respiratornim sincicijskim virusom. Respiratory syncytial virus infection in children. Paediatr Croat. 2018; 62 (Supl 1): 236-41. (XXXV. Seminar Hrvatske proljetne pedijatrijske škole u Splitu od 16. do 20. 04. 2018)
- Mori M, Kawashima H, Nakamura H, Nakagawa M, Kusuda S, Saji T, et al.; Surveillance Committee for Severe RSV Infection. Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan. J Infect Chemother. 2011;17(2):254-63. doi: 10.1007/s10156-010-0121-1
- Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, et al.; Motavizumab Cardiac Study Group. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res. 2011;70(2):186-91. doi: 10.1203/PDR.0b013e318220a553
- Beckhaus AA, Castro-Rodriguez JA. Down Syndrome and the Risk of Severe RSV Infection: A Meta-analysis. Pediatrics. 2018;142(3):e20180225. doi: 10.1542/peds.2018-0225
- Mori M, Onodera M, Morimoto A, Kosaka Y, Morio T, Notario GF, et al. Palivizumab use in Japanese infants and children with immunocompromised conditions. Pediatr Infect Dis J. 2014;33(11):1183-5. doi: 10.1097/INF.0000000000000392
- Committee on Infectious Diseases: collaborators: Bocchini Jr JA, Bernstein HH, Bradley JS, Brady MT, Byington CL, Fisher MC, et al. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694-701. doi: 10.1542/peds.2009-2345
- Gutfraind A, Galvani AP, Meyers LA. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection. JAMA Pediatr. 2015;169(4):341-8. doi: 10.1001/jama-pediatrics.2014.3804
- Sánchez Luna M, Pérez Muñuzuri A, Leante Castellanos JL, Ruiz Campillo CW, Sanz López E, Benavente Fernández I, et al.; en representación de la Comisión de Estándares de la Sociedad Española de Neonatología. Recomendaciones de la Sociedad Española de Neonatología para la utilización de palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial en lactantes de alto riesgo, actualización. [An update of the recommendations of the Spanish Neonatology Society for the use of palivizumab as prophylaxis for severe infections due to syncytial respiratory virus in high risk infants]. An Pediatr (Engl Ed). 2019;91(5):348-50. Spanish. doi: 10.1016/j.anpedi.2019.08.003
- American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415-20. doi: 10.1542/peds.2014-1665. Erratum in: Pediatrics. 2014;134(6):1221
- Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1
- Bacharier LB, Cohen R, Schweiger T, Yin-Declue H, Christie C, Zheng J, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2012;130(1):91-100.e3. doi: 10.1016/j.jaci.2012.02.010
- Gupta P, Beam BW, Rettiganti M. Temporal Trends of Respiratory Syncytial Virus-Associated Hospital and ICU Admissions Across the United States. Pediatr Crit Care Med. 2016;17(8):e343-51. doi: 10.1097/PCC.0000000000000850
- Mori M, Watabe S, Taguchi T, Hasegawa H, Ishige M, Tanuma N, et al. Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection. BMC Pediatr. 2021;21(1):106. doi: 10.1186/s12887-021-02567-6
- Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. J Med Econ. 2012;15(5):987-96. doi: 10.3111/13696998.2012.690013
- Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28(7):511-7. doi: 10.1038/jp.2008.28
- Kamori A, Morooka Y, Yamamura K, Chong PF, Kuga N, Takahata Y, et al. Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: A retrospective, observational study. Medicine (Baltimore). 2021;100(47):e27952. doi: 10.1097/MD.0000000000027952
- Yamagami H, Kimura H, Hashimoto T, Kusakawa I, Kusuda S. Detection of the Onset of the Epidemic Period of Respiratory Syncytial Virus Infection in Japan. Front Public Health. 2019;7:39. doi: 10.3389/fpubh.2019.00039
- Oliveira DB, Iwane MK, Prill MM, Weinberg GA, Williams JV, Griffin MR, et al. Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis. J Clin Virol. 2015;65:26-31. doi: 10.1016/j.jcv.2015.01.016
- Viguria N, Navascués A, Juanbeltz R, Echeverría A, Ezpeleta C, Castilla J. Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children. Hum Vaccin Immunother. 2021;17(6):1867-72. doi: 10.1080/21645515.2020.1843336